 |
인쇄하기
취소
|
Leading products shifting generations, ‘Sovaldi’ & ‘Daklinza’
The Korean outpatient prescription market is experiencing a shift in generations. Raising positions in the ranking, Gilead Sciences’ hepatitis C treatment ‘Sovaldi’ and BMS’s ‘Daklinza’ have taken the leading roles in the phenomenon.
On the other hand, BMS’s hepatitis B treatment ‘Baraclude’ and Pfizer’s ‘Celebrex’ have become victims of the phenomenon, still suffering from patent expiration.
...Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.